英硅智能(03696)与元羿生物拓展AI驱动CNS领域研发合作新合作总金额最高可达9475万美元_老虎社区_美港股上老虎

英硅智能(03696)与元羿生物拓展AI驱动CNS领域研发合作新合作总金额最高可达9475万美元

智通财经03-26

智通财经APP讯，英硅智能(03696)发布公告，在过去一年良好的合作关系基础上，英硅智能与Tenacia Biotechnology (Hongkong) Co., Limited(元羿生物)，一家致力于为未被满足的神经系统疾病患者开发创新治疗方案的商业化生物制药公司，已达成一项扩展的AI驱动研发合作。透过该合作，双方旨在为极具挑战性的神经系统疾病提供更广泛、更精准的治疗方案，从而降低后期研发...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

暂无评论

热议股票

7x24

全部

{"i18n":{"language":"zh_CN"},"data":{"share":"https://www.laohu8.com/m/news/2622568885?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2026-03-26 08:03","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2622568885","market":"fut","top_or_hot":-1,"title":"英硅智能(03696)与元羿生物拓展AI驱动CNS领域研发合作 新合作总金额最高可达9475万美元","media":"智通财经","content":"<div>\n<p>智通财经APP讯，英硅智能(03696)发布公告，在过去一年良好的合作关系基础上，英硅智能与Tenacia Biotechnology (Hongkong) Co., Limited(元羿生物)，一家致力于为未被满足的神经系统疾病患者开发创新治疗方案的商业化生物制药公司，已达成一项扩展的AI驱动研发合作。透过该合作，双方旨在为极具挑战性的神经系统疾病提供更广泛、更精准的治疗方案，从而降低后期研发...</p>\n\n<a href=\"http://www.zhitongcaijing.com/content/detail/1419193.html\">网页链接</a>\n\n</div>\n","source":"stock_zhitongcaijing","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>英硅智能(03696)与元羿生物拓展AI驱动CNS领域研发合作 新合作总金额最高可达9475万美元</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n英硅智能(03696)与元羿生物拓展AI驱动CNS领域研发合作 新合作总金额最高可达9475万美元\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-03-26 08:03 北京时间&nbsp;&nbsp;&nbsp;<a href=http://www.zhitongcaijing.com/content/detail/1419193.html><strong>智通财经</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>智通财经APP讯，英硅智能(03696)发布公告，在过去一年良好的合作关系基础上，英硅智能与Tenacia Biotechnology (Hongkong) Co., Limited(元羿生物)，一家致力于为未被满足的神经系统疾病患者开发创新治疗方案的商业化生物制药公司，已达成一项扩展的AI驱动研发合作。透过该合作，双方旨在为极具挑战性的神经系统疾病提供更广泛、更精准的治疗方案，从而降低后期研发...</p>\n\n<a href=\"http://www.zhitongcaijing.com/content/detail/1419193.html\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"03696","symbol_name":"英矽智能","start_time":0,"source_url":"http://www.zhitongcaijing.com/content/detail/1419193.html","article_id":"2622568885","we_media_id":null,"thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2622568885","pubTimestamp":1774483392,"columns":[],"sourceInfo":{"source_id":"stock_zhitongcaijing","name":"智通财经网"},"weMediaInfo":null,"summary":"智通财经APP讯，英硅智能 发布公告，在过去一年良好的合作关系基础上，英硅智能与Tenacia Biotechnology  Co., Limited，一家致力于为未被满足的神经系统疾病患者开发创新治疗方案的商业化生物制药公司，已达成一项扩展的AI驱动研发合作。本次拓展合作的总交易金额最高可达9475万美元。英硅智能有望获得元羿生物支付近期款项及里程碑款项等。","collect":0,"end_time":0,"defaultTopTitle":"zhitongcaijing.com","property":[],"viewcount":null,"language":"zh","relate_stocks":{"03696":"英矽智能","CNS":"科恩-斯蒂尔斯金融","AIPO":"Defiance AI and Power Infrastructure ETF","BK1141":"生命科学工具和服务","AGIX":"通用人工智能 ETF-AGIX","CHAT":"ROUNDHILL GENERATIVE AI & TECHNOLOGY ETF","BK4135":"资产管理与托管银行"},"translate_title":"Yingsi Intelligent (03696) and Yuanyi Biotech expand R&D cooperation in the field of AI-driven CNS. The total amount of new cooperation can reach US$94.75 million","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"AIPO":1.5,"03696":1.5,"CNS":1.5,"AGIX":1.5,"CHAT":1.5},"content_text":"智通财经APP讯，英硅智能(03696)发布公告，在过去一年良好的合作关系基础上，英硅智能与Tenacia Biotechnology (Hongkong) Co., Limited(元羿生物)，一家致力于为未被满足的神经系统疾病患者开发创新治疗方案的商业化生物制药公司，已达成一项扩展的AI驱动研发合作。透过该合作，双方旨在为极具挑战性的神经系统疾病提供更广泛、更精准的治疗方案，从而降低后期研发风险，并提升潜在的临床效益。根据相应协议条款，双方将利用生成式AI针对具有挑战性的神经类疾病，共同开发一款另具有特定属性的创新候选分子，并将其推进至临床前候选药物(PCC)阶段，以满足差异化的临床需求。本次拓展合作的总交易金额最高可达9475万美元。英硅智能有望获得元羿生物支付近期款项及里程碑款项等。","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"corporation","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"hasMoreComments":false,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"isCrawlerRequest":true}